GlassScriptPhysician profile
Carl Bruce Bowman
NPI 1093116774
$1,076.08
in general payments reported to CMS, 2019-2025
17 companies · $321 in 2025
The $321 reported for 2025 was more than what a typical Acute Care (Nurse Practitioner) provider received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $95.24 · 2022: $118 · 2023: $383 · 2024: $159 · 2025: $321.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $863.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $863.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $263.91 | 2021-2025 | Camzyos, Eliquis |
| Pfizer INC. | $179.37 | 2021-2025 | |
| Boston Scientific Corporation | $154.72 | 2023 | Watchman Access System |
| Philips North America LLC | $104.56 | 2024-2025 | Ambulatory Monitoring & Diagnostics Undivided, Mcot, (Ck4) Mcot |
| Janssen Pharmaceuticals, INC | $69.04 | 2022-2024 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $57.83 | 2025 | |
| Medtronic, INC. | $57.13 | 2021-2022 | |
| Heartflow, INC. | $34.65 | 2023-2025 | Ffrct |
| Novo Nordisk INC | $24.85 | 2024 | Ozempic, Rybelsus |
| Amgen INC. | $22.62 | 2023 | Repatha |
| Regeneron Healthcare Solutions, INC. | $17.49 | 2023 | Praluent, Evkeeza |
| Kiniksa Pharmaceuticals, LTD. | $17.33 | 2023 | Arcalyst |
| Alnylam Pharmaceuticals INC. | $17.28 | 2022 | |
| Merck Sharp & Dohme LLC | $16.04 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $14.55 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $12.42 | 2022 | |
| Abbott Laboratories | $12.29 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carl Bowman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.